ARMP Armata Pharmaceuticals Inc

Price (delayed)

$4.1

Market cap

$148.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.91

Enterprise value

$249.34M

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is ...

Highlights
The company's quick ratio fell by 22% QoQ but it rose by 16% YoY
The revenue is down by 18% year-on-year but it is up by 12% since the previous quarter
The equity has plunged by 189% YoY and by 159% from the previous quarter
The company's debt has surged by 147% YoY and by 6% QoQ

Key stats

What are the main financial stats of ARMP
Market
Shares outstanding
36.15M
Market cap
$148.21M
Enterprise value
$249.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
32.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.05
Earnings
Revenue
$4.53M
EBIT
-$66.42M
EBITDA
-$65.45M
Free cash flow
-$55.56M
Per share
EPS
-$1.91
Free cash flow per share
-$1.54
Book value per share
-$0.89
Revenue per share
$0.13
TBVPS
$2.63
Balance sheet
Total assets
$98.36M
Total liabilities
$130.43M
Debt
$120.37M
Equity
-$32.07M
Working capital
$2.69M
Liquidity
Debt to equity
-3.75
Current ratio
1.16
Quick ratio
1.37
Net debt/EBITDA
-1.55
Margins
EBITDA margin
-1,445.1%
Gross margin
100%
Net margin
-1,524.5%
Operating margin
-902.8%
Efficiency
Return on assets
-65.6%
Return on equity
N/A
Return on invested capital
-48.5%
Return on capital employed
-81.1%
Return on sales
-1,466.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARMP stock price

How has the Armata Pharmaceuticals stock price performed over time
Intraday
1.49%
1 week
15.82%
1 month
16.15%
1 year
156.25%
YTD
26.54%
QTD
26.54%

Financial performance

How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$4.53M
Gross profit
$4.53M
Operating income
-$40.89M
Net income
-$69.05M
Gross margin
100%
Net margin
-1,524.5%
The company's net margin has shrunk by 127% YoY and by 3.8% QoQ
The company's net income has shrunk by 87% YoY and by 16% QoQ
The company's operating margin fell by 35% YoY but it rose by 12% QoQ
The revenue is down by 18% year-on-year but it is up by 12% since the previous quarter

Growth

What is Armata Pharmaceuticals's growth rate over time

Valuation

What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
32.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.05
Armata Pharmaceuticals's EPS has shrunk by 77% YoY and by 16% QoQ
The equity has plunged by 189% YoY and by 159% from the previous quarter
ARMP's price to sales (P/S) is 76% higher than its last 4 quarters average of 18.6
The revenue is down by 18% year-on-year but it is up by 12% since the previous quarter

Efficiency

How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has shrunk by 119% YoY
Armata Pharmaceuticals's ROA has plunged by 76% YoY and by 15% from the previous quarter
ARMP's return on invested capital is down by 17% year-on-year but it is up by 3.8% since the previous quarter

Dividends

What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARMP.

Financial health

How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 25% lower than its total liabilities
The company's total liabilities has surged by 118% YoY and by 4.2% QoQ
ARMP's current ratio is down by 31% since the previous quarter but it is up by 6% year-on-year
The equity has plunged by 189% YoY and by 159% from the previous quarter
The company's debt has surged by 147% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.